Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain

被引:22
|
作者
Bonomi, Robin [1 ]
Mukhopadhyay, Uday [5 ]
Shavrin, Aleksandr [1 ]
Yeh, Hsien-Hsien [6 ,7 ]
Majhi, Anjoy [1 ]
Dewage, Sajeewa W. [3 ]
Najjar, Amer [4 ]
Lu, Xin [1 ]
Cisneros, G. Andres [3 ]
Tong, William P. [4 ]
Alauddin, Mian M. [4 ]
Liu, Ren-Shuan [6 ,7 ]
Mangner, Thomas J. [2 ]
Turkman, Nashaat [1 ]
Gelovani, Juri G. [1 ]
机构
[1] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA
[2] Wayne State Univ, Positron Emiss Tomog Ctr, Detroit, MI 48202 USA
[3] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Ctr Adv Biomed Imaging, Houston, TX 77030 USA
[6] Natl Yang Ming Univ, Natl Cyclotron & Radiochem Ctr, Taipei 112, Taiwan
[7] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan
来源
PLOS ONE | 2015年 / 10卷 / 08期
关键词
CENTRAL-NERVOUS-SYSTEM; IN-VIVO; CATALYTIC-ACTIVITY; INHIBITION; SPECIFICITY; ROLES; HDACS;
D O I
10.1371/journal.pone.0133512
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Histone deacetylases (HDAC's) became increasingly important targets for therapy of various diseases, resulting in a pressing need to develop HDAC class-and isoform-selective inhibitors. Class IIa deacetylases possess only minimal deacetylase activity against acetylated histones, but have several other client proteins as substrates through which they participate in epigenetic regulation. Herein, we report the radiosyntheses of the second generation of HDAC class IIa-specific radiotracers: 6-(di-fluoroacetamido)-1-hexanoicanilide (DFAHA) and 6-(tri-fluoroacetamido)-1-hexanoicanilide ([F-18]-TFAHA). The selectivity of these radiotracer substrates to HDAC class IIa enzymes was assessed in vitro, in a panel of recombinant HDACs, and in vivo using PET/CT imaging in rats. [F-18] TFAHA showed significantly higher selectivity for HDAC class IIa enzymes, as compared to [F-18] DFAHA and previously reported [F-18] FAHA. PET imaging with [F-18] TFAHA can be used to visualize and quantify spatial distribution and magnitude of HDAC class IIa expression-activity in different organs and tissues in vivo. Furthermore, PET imaging with [F-18] TFAHA may advance the understanding of HDACs class IIa mediated epigenetic regulation of normal and pathophysiological processes, and facilitate the development of novel HDAC class IIa-specific inhibitors for therapy of different diseases.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain
    Reid, Alicia E.
    Hooker, Jacob
    Shumay, Elena
    Logan, Jean
    Shea, Colleen
    Kim, Sung Won
    Collins, Shanika
    Xu, Youwen
    Volkow, Nora
    Fowler, Joanna S.
    NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (03) : 247 - 258
  • [42] Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain
    Tago, Tetsuro
    Toyohara, Jun
    Ishii, Kenji
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (04): : 746 - 755
  • [43] Synthesis of novel selective histone deacetylase inhibitors for the development of a suitable 18F-labelled radiotracer for the molecular imaging of HDAC1 in brain tumours
    Clauss, Oliver
    Toussaint, Magali
    Schaeker-Huebner, Linda
    Wenzel, Barbara
    Deuther-Conrad, Winnie
    Dukic-Stefanovic, Sladjana
    Ludwig, Friedrich-Alexander
    Guendel, Daniel
    Teodoro, Rodrigo
    Kopka, Klaus
    Brust, Peter
    Hansen, Finn
    Scheunemann, Matthias
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S215 - S216
  • [44] Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)
    Zhang, Kuojun
    Liu, Zhiyi
    Yao, Yiwu
    Qiu, Yatao
    Li, Feng
    Chen, Dong
    Hamilton, Dale J.
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 4020 - 4033
  • [45] PET imaging of sigma-2 receptor in the brain: Quantitative evaluation of three novel radiotracers in non-human primates
    Allui, Santosh Reddy
    Zheng, MingQiang
    Holden, Daniel
    Zhang, Ying
    Gao, Hong
    Zhang, Hui
    Crosby, Mallory
    Ropchan, Jim
    Labaree, David
    Carson, Richard
    Jia, Hongmei
    Huang, Yiyun
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [46] Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement
    Salian-Mehta, Smita
    Xu, Mei
    McKinsey, Timothy A.
    Tobet, Stuart
    Wierman, Margaret E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (22) : 14045 - 14056
  • [47] Identification of Selective Class II Histone Deacetylase Inhibitors Using a Novel Dual-Parameter Binding Assay Based on Fluorescence Anisotropy and Lifetime
    Haus, Patricia
    Korbus, Michael
    Schroeder, Michael
    Meyer-Almes, Franz-Josef
    JOURNAL OF BIOMOLECULAR SCREENING, 2011, 16 (10) : 1206 - 1216
  • [48] The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1-and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
    Wu, Chung-Pu
    Lusvarghi, Sabrina
    Wang, Jyun-Cheng
    Hsiao, Sung-Han
    Huang, Yang-Hui
    Hung, Tai-Ho
    Ambudkar, Suresh V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [49] A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours
    Eskens, F.
    van Doorn, L.
    Papadatos-Pastos, D.
    Debnam, P.
    Tall, M.
    Toal, M.
    Hooftman, L.
    Verweij, J.
    Banerji, U.
    EJC SUPPLEMENTS, 2010, 8 (07): : 125 - 125
  • [50] Non-invasive molecular imaging of SIRT1-mediated epigenetic regulation in cancer using PET/CT with a novel substrate-type radiotracer 2-[18F]PhAHA
    Bonomi, Robin E.
    Laws, Maxwell
    Shavrin, Aleksandr
    Mangner, Thomas
    Gelovani, Juri G.
    CANCER RESEARCH, 2016, 76